Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABINA: MEN1611 and Eribulin in PIK3CA/PTEN-altered Advanced Breast Cancer
NCT05810870Phase 2Active, not recruiting
- Sponsor
- MEDSIR
- Start
- May 2023
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of izorlisib in breast cancer, metaplastic breast carcinoma (MBC) and triple-negative breast cancer (TNBC), sponsored by MEDSIR. Started May 2023; status: active, not recruiting.
02
Drugs
izorlisib
03
Conditions
breast cancermetaplastic breast carcinoma (MBC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05810870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05810870.